Skip to main content
Top
Published in: Acta Neurologica Belgica 1/2021

01-02-2021 | Multiple Sclerosis | Original article

Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990–2016

Authors: Masoud Ghiasian, Mohammad Faryadras, Maryam Mansour, Elham Khanlarzadeh, Shahir Mazaheri

Published in: Acta Neurologica Belgica | Issue 1/2021

Login to get access

Abstract

Multiple sclerosis (MS) is the most common inflammatory demyelinating disease in the central nervous system. It is one of the major causes of disability in young adults. Early diagnosis and treatment of this disease could decrease later disability and additional costs. In this cross-sectional analytical study, a total of 351 patients were selected from among the multiple sclerosis patients that went to MS clinic or neurologic clinic in 1990–2016. Data were collected and analysed by SPSS v16. This study was conducted on 82.6% females and 17.4% males. Family history of MS was positive in 12.8% of cases. Mean time of onset of symptoms till first medical visit was 3.25 months. Mean time from first medical visit to diagnosis was 14.98 months. Mean time from onset of symptoms till diagnosis was 18.01 months and the mean time from onset of symptoms till initiation of treatment was 18.73 months. Also, 29.3% of cases had delay in first medical visit and 42.2% of cases had delay in diagnosis of MS more than 6 weeks from first medical visit. Overall, delay in first medical visit and diagnosis of MS has decreased over the years. However, there is still delay in diagnosis of MS. Factors associated with delay are low education, male gender, living in rural areas, primary progressive MS, age at MS diagnosis and first clinical symptoms.
Literature
1.
go back to reference Ropper AH (2005) Adams and Victor’s principles of neurology: McGraw-Hill Medical Pub. Division New York Ropper AH (2005) Adams and Victor’s principles of neurology: McGraw-Hill Medical Pub. Division New York
2.
go back to reference Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL (2015) Bradley’s Neurology in Clinical Practice E-Book: Elsevier Health Sciences Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL (2015) Bradley’s Neurology in Clinical Practice E-Book: Elsevier Health Sciences
3.
go back to reference Merritt HH (2010) Merritt’s neurology: Lippincott Williams & Wilkins Merritt HH (2010) Merritt’s neurology: Lippincott Williams & Wilkins
4.
go back to reference Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi S-H, Akbari M et al (2013) Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol 70(5–6):356–363CrossRef Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi S-H, Akbari M et al (2013) Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol 70(5–6):356–363CrossRef
5.
go back to reference Etemadifar M, Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Nasr Z (2014) Estimated prevalence and incidence of multiple sclerosis in Iran. Eur Neurol 72(5–6):370–374CrossRef Etemadifar M, Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Nasr Z (2014) Estimated prevalence and incidence of multiple sclerosis in Iran. Eur Neurol 72(5–6):370–374CrossRef
6.
go back to reference Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938–952CrossRef Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):938–952CrossRef
7.
go back to reference Weinshenker BG, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J et al (1989) The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain 112(1):133–146CrossRef Weinshenker BG, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J et al (1989) The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain 112(1):133–146CrossRef
8.
go back to reference Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED (1998) A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 4(5):419–425CrossRef Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED (1998) A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 4(5):419–425CrossRef
9.
go back to reference Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Livingston T, Vollmer T et al (2014) Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord 3(2):227–236CrossRef Campbell JD, Ghushchyan V, McQueen RB, Cahoon-Metzger S, Livingston T, Vollmer T et al (2014) Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates. Mult Scler Relat Disord 3(2):227–236CrossRef
10.
go back to reference Grima D, Torrance G, Francis G, Rice G, Rosner A, Lafortune L (2000) Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 6(2):91–98CrossRef Grima D, Torrance G, Francis G, Rice G, Rosner A, Lafortune L (2000) Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 6(2):91–98CrossRef
11.
go back to reference Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B (2006) Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 77(8):918–926CrossRef Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B (2006) Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 77(8):918–926CrossRef
12.
go back to reference Sobocki P, Pugliatti M, Lauer K, Kobelt G (2007) Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler 13(8):1054–1064CrossRef Sobocki P, Pugliatti M, Lauer K, Kobelt G (2007) Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler 13(8):1054–1064CrossRef
13.
go back to reference Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP et al (2002) Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51(4):481–490CrossRef Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP et al (2002) Interferon β-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51(4):481–490CrossRef
14.
go back to reference Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343(13):898–904CrossRef Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343(13):898–904CrossRef
15.
go back to reference Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller DH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397CrossRef Kappos L, Freedman MS, Polman CH, Edan G, Hartung H-P, Miller DH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389–397CrossRef
16.
go back to reference Kappos L, Polman C, Freedman M, Edan G, Hartung H, Miller D et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7):1242–1249CrossRef Kappos L, Polman C, Freedman M, Edan G, Hartung H, Miller D et al (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67(7):1242–1249CrossRef
17.
go back to reference Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F (2008) B cells and multiple sclerosis. Lancet Neurol 7(9):852–858CrossRef Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F (2008) B cells and multiple sclerosis. Lancet Neurol 7(9):852–858CrossRef
18.
go back to reference Comi G (2009) Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 31(6):1142–1157CrossRef Comi G (2009) Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 31(6):1142–1157CrossRef
19.
go back to reference Goodin D, Bates D (2009) Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler 15(10):1175–1182CrossRef Goodin D, Bates D (2009) Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler 15(10):1175–1182CrossRef
20.
go back to reference Edan G, Kappos L, Montalbán X, Polman C, Freedman M, Hartung H-P et al (2013) Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 85(11):1183–1189CrossRef Edan G, Kappos L, Montalbán X, Polman C, Freedman M, Hartung H-P et al (2013) Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 85(11):1183–1189CrossRef
21.
go back to reference Kennedy P (2013) Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis. J Neurosci Nurs 45(6):S3–S13CrossRef Kennedy P (2013) Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis. J Neurosci Nurs 45(6):S3–S13CrossRef
22.
go back to reference Noyes K, Weinstock-Guttman B (2013) Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 19(17 Suppl):s321–s331PubMed Noyes K, Weinstock-Guttman B (2013) Impact of diagnosis and early treatment on the course of multiple sclerosis. Am J Manag Care 19(17 Suppl):s321–s331PubMed
23.
go back to reference Fernández O, Fernández V, Arbizu T, Izquierdo G, Bosca I, Arroyo R et al (2010) Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study). J Neurol 257(9):1500–1507CrossRef Fernández O, Fernández V, Arbizu T, Izquierdo G, Bosca I, Arroyo R et al (2010) Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study). J Neurol 257(9):1500–1507CrossRef
24.
go back to reference Adamec I, Barun B, Gabelić T, Zadro I, Habek M (2013) Delay in the diagnosis of multiple sclerosis in Croatia. Clin Neurol Neurosurg 115:S70–S72CrossRef Adamec I, Barun B, Gabelić T, Zadro I, Habek M (2013) Delay in the diagnosis of multiple sclerosis in Croatia. Clin Neurol Neurosurg 115:S70–S72CrossRef
25.
go back to reference Kelly S, Chaila E, Kinsella K, Duggan M, McGuigan C, Tubridy N et al (2011) Multiple sclerosis, from referral to confirmed diagnosis: an audit of clinical practice. Mult Scler 17(8):1017–1021CrossRef Kelly S, Chaila E, Kinsella K, Duggan M, McGuigan C, Tubridy N et al (2011) Multiple sclerosis, from referral to confirmed diagnosis: an audit of clinical practice. Mult Scler 17(8):1017–1021CrossRef
26.
go back to reference Wutayd OA (2016) Delay in the diagnosis of multiple sclerosis. Int J Healthcare Sci 4(2):427–428 Wutayd OA (2016) Delay in the diagnosis of multiple sclerosis. Int J Healthcare Sci 4(2):427–428
27.
go back to reference Kingwell E, Leung AL, Roger E, Duquette P, Rieckmann P, Tremlett H (2010) Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci 292(1):57–62CrossRef Kingwell E, Leung AL, Roger E, Duquette P, Rieckmann P, Tremlett H (2010) Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci 292(1):57–62CrossRef
Metadata
Title
Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990–2016
Authors
Masoud Ghiasian
Mohammad Faryadras
Maryam Mansour
Elham Khanlarzadeh
Shahir Mazaheri
Publication date
01-02-2021
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 1/2021
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-020-01528-7

Other articles of this Issue 1/2021

Acta Neurologica Belgica 1/2021 Go to the issue